Table 1.

Demographics of 808 study and 490 excluded patients

	Mean ± SD Study Group/Median (range)	Mean ± SD Excluded Group/Median (range)	p Value
At diagnosis:
Age	65.4 ± 5.7/66 (41–83)	65.7 ± 6.1/66 (41–92)	0.01
PSA (ng/ml)	5.2 ± 2.6/4.8 (0.18–24)	5.2 ± 2.8/4.8 (0.18–24)	0.40
PSAD (ng/ml/cc)	0.16± 0.06/0.10 (0.02–0.69)	0.11± 0.06/0.10 (0.004–0.69)	0.03
% Free PSA*	19.3 ± 7.2/18.0 (5–44)	18.2 ± 7.3/17.2 (4–50)	0.30
No. pos cores	1.4 ± 0.7/1.0 (1–7)	1.3 ± 0.7/1.0 (1–7)	0.04
Max % any pos core involvement	10.6 ± 14.7/5.0 (1–100)	10.0 ± 14.7/5.0 (1–100)	0.20
Time to 1st surveillance biopsy (mos)	11.0 ± 3.7/12.0 (1–18)	12.4 ± 8.2/12.0 (1–91)	<0.0001
Time between subsequent surveillance biopsies (mos)	12.6 ± 2.0/12.0 (2–18)	14.5 ± 6.8/12.0 (0–131)	<0.0001
No. repeat biopsies after diagnosis until reclassification	3 ± 2.3/2 (0–11)	3 ± 2.0/2 (0–12)	0.60

^*Not measured in all patients.